David Arkowitz Insider Trading $SBPH F-star Therapeutics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for David Arkowitz.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David Arkowitz. David Arkowitz is Chief Financial Officer in IDENIX PHARMACEUTICALS INC ($IDIX) and Chief Financial Officer in Flexion Therapeutics Inc ($FLXN) and Director in PROTEOSTASIS THERAPEUTICS, INC. ($PTI) and Director in Spring Bank Pharmaceuticals, Inc. ($SBPH).
David Arkowitz in F-star Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of David Arkowitz: Director
Holdings: 37,929 shares
Current Value: $284,468
Latest Transaction: Jun 07 2021
$SBPH Market Capitalization: $58.25M
$SBPH Previous Close: $7.50
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of David Arkowitz in F-star Therapeutics, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, SBPH, FLXN, IDIX, YMTX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 07 2021 | SBPH | F-star Therapeutic ... | Arkowitz David | Director | Option Exercise | A | 6.88 | 20,000 | 137,600 | 20,000 | |
| Jun 25 2020 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 1.60 | 7,500 | 12,000 | 7,500 | |
| Jan 02 2020 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 9,098 | 0 | 37,929 | 28.8 K to 37.9 K (+31.56 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 4,179 | 0 | 28,831 | 24.7 K to 28.8 K (+16.95 %) |
| Oct 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 4,179 | 0 | 28,831 | 24.7 K to 28.8 K (+16.95 %) |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 11 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 4.62 | 7,500 | 34,650 | 7,500 | |
| Jul 01 2019 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 0.00 | 3,896 | 0 | 24,652 | 20.8 K to 24.7 K (+18.77 %) |
| Jun 19 2018 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 13.99 | 5,500 | 76,945 | 5,500 | |
| Aug 07 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Buy | P | 12.24 | 2,300 | 28,152 | 19,386 | 17.1 K to 19.4 K (+13.46 %) |
| Aug 07 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Buy | P | 12.25 | 200 | 2,450 | 17,086 | 16.9 K to 17.1 K (+1.18 %) |
| Jun 16 2017 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 14.27 | 5,500 | 78,485 | 5,500 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 10.79 | 4,386 | 47,325 | 4,386 | |
| Nov 23 2016 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Grant | A | 9.12 | 4,386 | 40,000 | 16,886 | 12.5 K to 16.9 K (+35.09 %) |
| Jul 29 2016 | SBPH | Spring Bank Pharma ... | Arkowitz David | Director | Option Exercise | A | 9.05 | 5,500 | 49,775 | 5,500 |
Page: 1